蛋白亚单位疫苗生产

相关技术文章

• Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium
  See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.
• CHO平台
  我们开发了多种工具，可让您比以往更快、更轻松地为您特定的CHO克隆开发优化的培养基配方。
• BugBuster® and Benzonase® Reagents are the Clear Solutions to Simple, Efficient Extraction of E. coli Proteins
  This article shows the use of BugBuster® and Benzonase® as protein purification tools to extract recombinant proteins from E. coli and to reduce the viscosity of the extract.
• Choosing the Optimal Vaccine Adjuvant
  Adjuvant selection is dependent on vaccine formulation and individual application. Effectiveness and safety are of primary importance in adjuvant selection, yet a number of other characteristics must be considered.
• Cost Modeling Vaccine Manufacturing: Estimate Production Costs for mRNA and other Vaccine Modalities
  A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
• Virus-like Particle (VLP) Vaccine Bioprocessing and Formulation Steps
  This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.
• mRNA疫苗和治疗制剂生产策略
  mRNA技术采用非病毒递送系统，具有极高的多样性。将mRNA递送到细胞的胞质溶胶中可诱导目的蛋白表达，发挥治疗性或预防性作用，作为抗原刺激机体产生免疫反应获得免疫保护，替代有缺陷的蛋白功能或激活抗肿瘤反应。
• 疫苗和药物开发用mRNA合成
  了解 mRNA 疫苗如何诱导免疫，以及如何为疫苗免疫原和其他生物制药制备合成 mRNA。寻找合成 mRNA 所需的试剂。